Insight into Antibiotic Synergy Combinations for Eliminating Colistin Heteroresistant Klebsiella pneumoniae

Colistin heteroresistance has been identified in several bacterial species, including Escherichia coli and Klebsiella pneumoniae, and may underlie antibiotic therapy failures since it most often goes undetected by conventional antimicrobial susceptibility tests. This study utilizes population analysis profiling (PAP) and time–kill assay for the detection of heteroresistance in K. pneumoniae and for evaluating the association between in vitro regrowth and heteroresistance. The mechanisms of colistin resistance and the ability of combination therapies to suppress resistance selection were also analysed. In total, 3 (18%) of the 16 colistin-susceptible strains (MIC ≤ 2 mg/L) were confirmed to be heteroresistant to colistin by PAP assay. In contrast to the colistin-susceptible control strains, all three heteroresistant strains showed regrowth when exposed to colistin after 24 h following a rapid bactericidal action. Colistin resistance in all the resistant subpopulations was due to the disruption of the mgrB gene by various insertion elements such as ISKpn14 of the IS1 family and IS903B of the IS5 family. Colistin combined with carbapenems (imipenem, meropenem), aminoglycosides (amikacin, gentamicin) or tigecycline was found to elicit in vitro synergistic effects against these colistin heteroresistant strains. Our experimental results showcase the potential of combination therapies for treatment of K. pneumoniae infections associated with colistin heteroresistance.

[1]  J. Mathias,et al.  International manufacturing and trade in colistin, its implications in colistin resistance and One Health global policies: a microbiological, economic, and anthropological study. , 2023, The Lancet. Microbe.

[2]  R. Sierra,et al.  Antibiotic heteroresistance in ESKAPE pathogens, from bench to bedside. , 2022, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[3]  D. Y. Çiftdoğan,et al.  Colistin Treatment for Multidrug-Resistant Gram-Negative Infections in Children: Caution Required for Nephrotoxicity , 2022, Sisli Etfal Hastanesi tip bulteni.

[4]  Zhancheng Gao,et al.  Heteroresistance Is Associated With in vitro Regrowth During Colistin Treatment in Carbapenem-Resistant Klebsiella pneumoniae , 2022, Frontiers in Microbiology.

[5]  J. A. Lepe,et al.  Mecanismos de resistencia en bacterias gramnegativas , 2022, Medicina Intensiva.

[6]  E. Sheridan,et al.  Prevalence of insertion sequence elements in plasmids relating to mgrB gene disruption causing colistin resistance in Klebsiella pneumoniae , 2022, MicrobiologyOpen.

[7]  Yuan Tian,et al.  Combined effect of Polymyxin B and Tigecycline to overcome Heteroresistance in Carbapenem-Resistant Klebsiella pneumoniae , 2021, Microbiology spectrum.

[8]  Zhancheng Gao,et al.  In vitro and in vivo synergistic effects of tigecycline combined with aminoglycosides on carbapenem-resistant Klebsiella pneumoniae. , 2021, The Journal of antimicrobial chemotherapy.

[9]  K. Ko,et al.  Detection of colistin-resistant populations prior to antibiotic exposure in KPC-2-producing Klebsiella pneumoniae clinical isolates , 2021, Journal of Microbiology.

[10]  J. Osei Sekyere,et al.  Emerging Transcriptional and Genomic Mechanisms Mediating Carbapenem and Polymyxin Resistance in Enterobacteriaceae: a Systematic Review of Current Reports , 2020, mSystems.

[11]  H. Bello-Toledo,et al.  Colistin Heteroresistance among Extended Spectrum β-lactamases-Producing Klebsiella pneumoniae , 2020, Microorganisms.

[12]  C. Vilaplana,et al.  Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial , 2020, Critical Care.

[13]  Yongjun Wu,et al.  Klebsiella pneumoniae: an increasing threat to public health , 2020, Annals of Clinical Microbiology and Antimicrobials.

[14]  Y. Doi,et al.  Colistin and its role in the Era of antibiotic resistance: an extended review (2000–2019) , 2020, Emerging microbes & infections.

[15]  B. Berglund.  Acquired Resistance to Colistin via Chromosomal And Plasmid-Mediated Mechanisms in Klebsiella pneumoniae , 2019, Infectious Microbes and Diseases.

[16]  K. Ko,et al.  Colistin Heteroresistance in Klebsiella Pneumoniae Isolates and Diverse Mutations of PmrAB and PhoPQ in Resistant Subpopulations , 2019, Journal of clinical medicine.

[17]  D. Andersson,et al.  Mechanisms and clinical relevance of bacterial heteroresistance , 2019, Nature Reviews Microbiology.

[18]  E. Burd,et al.  Antibiotic combinations that exploit heteroresistance to multiple drugs effectively control infection , 2019, Nature Microbiology.

[19]  Victor I Band,et al.  Heteroresistance: A cause of unexplained antibiotic treatment failure? , 2019, PLoS pathogens.

[20]  K. Ganbarov,et al.  Molecular mechanisms related to colistin resistance in Enterobacteriaceae , 2019, Infection and drug resistance.

[21]  R. Mirnejad,et al.  Antimicrobial Susceptibility Testing for Polymyxins: Challenges, Issues, and Recommendations , 2018, Journal of Clinical Microbiology.

[22]  P. Plésiat,et al.  Resistance to polymyxins in Gram-negative organisms. , 2017, International journal of antimicrobial agents.

[23]  J. Rolain,et al.  Deciphering Heteroresistance to Colistin in a Klebsiella pneumoniae Isolate from Marseille, France , 2017, Antimicrobial Agents and Chemotherapy.

[24]  P. Nordmann,et al.  Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes , 2017, Clinical Microbiology Reviews.

[25]  Malbert R. C. Rogers,et al.  Genomic Characterization of Colistin Heteroresistance in Klebsiella pneumoniae during a Nosocomial Outbreak , 2016, Antimicrobial Agents and Chemotherapy.

[26]  M. Valvano,et al.  Antimicrobial Heteroresistance: an Emerging Field in Need of Clarity , 2015, Clinical Microbiology Reviews.

[27]  V. di Pilato,et al.  MgrB Inactivation Is a Common Mechanism of Colistin Resistance in KPC-Producing Klebsiella pneumoniae of Clinical Origin , 2014, Antimicrobial Agents and Chemotherapy.

[28]  D. Landman,et al.  Irreproducible and Uninterpretable Polymyxin B MICs for Enterobacter cloacae and Enterobacter aerogenes , 2013, Journal of Clinical Microbiology.

[29]  M. Falagas,et al.  Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[30]  D. Sofianou,et al.  Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae. , 2011, The Journal of antimicrobial chemotherapy.

[31]  J. Turnidge,et al.  In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. , 2008, The Journal of antimicrobial chemotherapy.

[32]  U. Ullmann,et al.  Pharmacokinetics of imipenem in patients undergoing major colon surgery , 1990, Infection.

[33]  OUP accepted manuscript , 2022, Clinical Infectious Diseases.

[34]  P. Nordmann,et al.  The mgrB gene as a key target for acquired resistance to colistin in Klebsiella pneumoniae. , 2015, The Journal of antimicrobial chemotherapy.